CD274 and neoplasm: Rather than assessing only the PD-L1/CD274 expression of tumor cells, the additional monitoring of PD-L1/CD274 expression of immune cells in the blood appears to be mandatory for predicting therapy responses in patients undergoing checkpoint blockade therapy.